Preliminary evaluation of prostate cancer metastatic risk biomarkers

International Journal of Biological Markers

Volumn 20, Issue 3, 2005, Pages 141-145

  Paris, P L ^a   Weinberg, V ^a   Simko, J ^b   Andaya, A ^a   Albo, G ^a,c   Rubin, M A ^d   Carroll, P R ^a   Collins, C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Metastasis; Prostate cancer; Risk

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BIOCHEMISTRY; CANCER CLASSIFICATION; CANCER RISK; CLINICAL ARTICLE; CLONE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EXPERIMENTATION; GENE LOCUS; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NOMOGRAM; OUTCOMES RESEARCH; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; COMPARATIVE STUDY; EVALUATION; GENOMICS; METHODOLOGY; MICROARRAY ANALYSIS; MULTIMODALITY CANCER THERAPY; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

BACTERIA (MICROORGANISMS);

COMBINED MODALITY THERAPY; GENOMICS; HUMANS; MALE; MICROARRAY ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NUCLEIC ACID HYBRIDIZATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744530171     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080502000301     Document Type: Article

References (24)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States in over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172 (4 Pt 1): 1297-301.
3. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21: 3573-9.
4. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904.
5. Morote J, Trilla E, Esquena S, et al. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. Int J Biol Markers 2002; 17: 239-43.
6. Schmidt H, De Angelis G, Bettendorf O, et al. Frequent detection and immunophenotyping of prostate-derived cell clusters in the peripheral blood of prostate cancer patients. Int J Biol Markers 2004; 19: 93-9.
7. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
8. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71.
9. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18: 3352-9.
10. Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med 2003; 22: 3515-25.
11. Ross PL, Gerigk C, Gonen M, et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20: 82-8.
12. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003; 13: 111-6.
13. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165: 1562-8.
14. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113: 913-23.
15. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203-9.
16. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-11.
17. Veltman JA, Fridlyand J, Pejavar S, et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 2872-80.
18. Snijders AM, Nowee ME, Fridlyand J, et al. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 2003; 22: 4281-6.
19. Wilhelm M, Veltman JA, Olshen AB, et al. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 2002; 62: 957-60.
20. Paris PL, Andaya A, Fridlyand J, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004; 13: 1303-13.
21. Paris PL, Albertson DG, Alers JC, et al. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol 2003; 162: 763-70.
22. Fridlyand J, Snijders AM, Pinkel D, Albertson DG, Jain A. Application of Hidden Markov Models to the analysis of the array CGH data. Journal of Multivariate Analysis (Special Genomic Issue) 2004; 90: 132-53.
23. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21: 566-76.
24. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208-15.